QR12000
Small molecule
Evidence outlook · registrational
Hypertension: registrational trial registered, not yet recruiting
Entered Phase 3 on partial signal mid-stage evidence. The registry's posted readout date (2026-04-30) has passed without a status update. Check News for topline announcements.
NCT07700875: The study was a randomized, quadruple-masked, active-controlled trial with 391 participants and a clinical hypertension endpoint: change in mean sitting systolic blood pressure at Week 8. Because the registry provides no primary-endpoint results, the outcome is unknown and the trial cannot be rated as strong evidence despite its robust design.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06716970 NCT06716970 · Essential Hypertension Registry: NCT06716970 | 3 | Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) (Baseline and week 8) 2026-04-30 | In progress: primary completion was expected 30 Apr 2026; results not posted | not yet graded | link ↗ |
View 1 more trial
NCT07700875 NCT07700875 · Essential Hypertension The study was a randomized, quadruple-masked, active-controlled trial with 391 participants and a clinical hypertension endpoint: change in mean sitting systolic blood pressure at Week 8. Because the registry provides no primary-endpoint results, the outcome is unknown and the trial cannot be rated as strong evidence despite its robust design. Registry: NCT07700875 | 2 | Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8 (Baseline and week 8.) 2023-08-20 | Results not posted; external-source review pending | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Hypertension: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| QR12000: this drug | Phase 3 | Small molecule | AT1R; neprilysin | Partial signal | No reviewed efficacy summary in this indication | |
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | Reliable signal | NCT03541174: Week 4 sitting systolic blood pressure change: -15.26 vs -11.47 mmHg placebo for aprocitentan 12.5 mg; difference -3.79 mmHg (p=0.0042). For aprocitentan 25 mg: -15.20 vs -11.47 mmHg placebo; difference -3.73 mmHg (p=0.0046). | |
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | Reliable signal | NCT06168409: Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001). NCT06034743: Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat (At Week 12): Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg -15.7 mmHg (Standard Error 1) vs Double-Blind Treatment Period Weeks 0-12 Placebo -5.8 mmHg (Standard Error 1) | |
| Propranolol (Inderal LA) | Approved | Small molecule | Beta-1/beta-2 adrenergic receptors | not yet graded | No reviewed efficacy summary in this indication | |
| AD-209 | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | Partial signal | NCT06348576: Week-8 sitting systolic blood pressure: non-inferiority and superiority vs telmisartan 40 mg confirmed in the full analysis set (published Phase III, 2026-02-20). | |
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | Partial signal | No reviewed efficacy summary in this indication | |
| Amlodipine / Valsartan / Rosuvastatin (CJ-30060) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | Partial signal | No reviewed efficacy summary in this indication | |
| DWC202206 + DWC202207 | Phase 3 | Small molecule | — | Partial signal | No reviewed efficacy summary in this indication | |
| Esaxerenone (Minnebro) | Phase 3 | Small molecule | Mineralocorticoid receptor | Partial signal | NCT02722265: Change from baseline in sitting SBP/DBP, overall population (n=368): -16.1/-7.7 mmHg at week 12, -18.9/-9.9 mmHg at week 28, -23.1/-12.5 mmHg at week 52 (all 95% CI given); monotherapy subgroup (n=245): -16.3/-7.0 mmHg at week 12, -23.7/-12.3 mmHg at week 52 NCT02807987: Change from baseline in sitting SBP/DBP at end of treatment (Week 12), add-on-to-ARB/ACEI group (n=58): -17.8 mmHg SBP (95% CI -21.0 to -14.7), -8.1 mmHg DBP (95% CI -9.7 to -6.5), p<0.001 | |
| Fimasartan / Atorvastatin / Ezetimibe (BR1017) | Phase 3 | Small molecule | AT1 receptor; NPC1L1; HMG-CoA reductase | Partial signal | NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025). | |
| Levamlodipine / Valsartan (SYH9056) | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel (dual) | Partial signal | NCT06771245: Blood-pressure lowering significantly superior to levamlodipine or valsartan monotherapy (sponsor, 2026-06-16). | |
| Lorundrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | Reliable signal | NCT06153693: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) NCT05769608: Placebo-adjusted change in 24-hour average ambulatory SBP at Week 12: -7.9 mmHg (lorundrostat 50 mg arm) | |
| Olmesartan / Rosuvastatin (DWJ1276) (Olostar) | Phase 3 | Small molecule | Angiotensin II receptor / HMG-CoA reductase | Partial signal | NCT01764295: LDL-C percent change from baseline at week 8 (LS mean, SE): DWJ1276 (FDC) -52.3% (2.8%) vs olmesartan alone -0.6% (3.5%) vs rosuvastatin alone -46.9% (3.5%) vs placebo -3.2% (3.9%); FDC vs olmesartan difference -51.7% (95% CI -59.8% to -43.6%, P<0.0001). | |
| Orforglipron (Foundayo) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Sacubitril / Valsartan (Entresto) | Phase 3 | Small molecule | Neprilysin + Angiotensin II receptor (dual) | Partial signal | NCT01599104: Mean sitting systolic BP reduction from baseline at week 8 vs olmesartan (LCZ696/Entresto, Japanese essential hypertension): sacubitril/valsartan 200mg difference -5.01 mmHg (95% CI -6.95 to -3.06, P<0.001 for noninferiority and superiority); 400mg difference -6.97 mmHg (95% CI -8.92 to -5.03, P<0.001). NCT01593787: 43.8% (14/32) of patients reported at least one adverse event (mild severity; 0% serious AEs, 0% deaths); mean sitting SBP reduction 20.5±11.3 mmHg and mean sitting DBP reduction 8.3±6.3 mmHg from baseline to Week 8 (Total LCZ696 group, N=32); geometric mean UACR reduction 15.1%. | |
| Safiglipron (HRS-7535) | Phase 3 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| SAL0120 | Phase 3 | Small molecule | Endothelin receptor type A (ETA) | not yet graded | No reviewed efficacy summary in this indication | |
| Valsartan / Amlodipine / Chlorthalidone (AJU-C52) | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | Reliable signal | NCT06416865: Change in MSSBP from baseline to week 8: between-group difference of -10.99 (valsartan/amlodipine/chlorthalidone vs valsartan/amlodipine control) | |
| Vicadrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| Zilebesiran | Phase 3 | RNA / oligonucleotide | Angiotensinogen (AGT) | Reliable signal | NCT04936035: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Placebo 6.8 millimeters of mercury (mmHg) ± 1.58 vs Zilebesiran 150 mg Q6M -7.3 millimeters of mercury (mmHg) ± 1.49 vs Zilebesiran 300 mg Q6M and Q3M -10.0 millimeters of mercury (mmHg) ± 1.05 vs Zilebesiran 600 mg Q6M -8.9 millimeters of mercury (mmHg) ± 1.52; p=<0.0001 (Placebo vs Zilebesiran 300 mg Q6M and Q3M), p=<0.0001 (Placebo vs Zilebesiran 600 mg Q6M) | |
| HRS-9563 | Phase 2 | RNA / oligonucleotide | AGT (angiotensinogen) mRNA | not yet graded | No reviewed efficacy summary in this indication | |
| IBI3016 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| QCZ484 | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| QLS1410 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| RTN-001 | Phase 2 | Small molecule | PDE5 | not yet graded | No reviewed efficacy summary in this indication | |
| SAL0140 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| Tonlamarsen | Phase 2 | RNA / oligonucleotide | Angiotensinogen (AGT) | Partial signal | NCT06864104: Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. NCT05314439: (-6% v. -79%, PBO v. 90 mg, p=0.001); median AGT reductions (-5% v. -86%, PBO v. 90 mg) | |
| VB19055 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | not yet graded | No reviewed efficacy summary in this indication | |
| VCT220 | Phase 2 | Small molecule | GLP-1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| BEBT-701 | Phase 1/2 | RNA / oligonucleotide | Angiotensinogen (AGT) / PCSK9 (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| ADX-850 | Phase 1 | RNA / oligonucleotide | Angiotensinogen (AGT) | not yet graded | No reviewed efficacy summary in this indication | |
| Carvedilol (CKD-385) | Phase 1 | Small molecule | Beta-adrenergic receptors (nonselective) and alpha-1 adrenergic receptor (antagonist) | Partial signal | No reviewed efficacy summary in this indication | |
| HJB647 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10522 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| JX09 | Phase 1 | Small molecule | Aldosterone synthase (CYP11B2) | Partial signal | No reviewed efficacy summary in this indication | |
| KK3910 | Phase 1 | Biologic (subtype unspecified) | — | not yet graded | No reviewed efficacy summary in this indication | |
| KN060 | Phase 1 | Monoclonal antibody | Factor XI/XIa (FXI/FXIa) | not yet graded | No reviewed efficacy summary in this indication | |
| LivaloV | Phase 1(overall) | Small molecule | HMG-CoA reductase / Angiotensin II type 1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Long-Acting ANP Analog (LY3971297) | Phase 1 | Peptide | Natriuretic peptide receptor (NPR-A) | not yet graded | No reviewed efficacy summary in this indication | |
| Nurandociguat | Phase 1 | Small molecule | Soluble guanylate cyclase | Weak signal | No reviewed efficacy summary in this indication | |
| SHR-4658 | Phase 1(overall) | Peptide | — | not yet graded | No reviewed efficacy summary in this indication | |
| C2402 | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Candesartan / Amlodipine | —(overall) | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel | not yet graded | No reviewed efficacy summary in this indication | |
| DehydraTECH-CBD | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Lercanidipine | —(overall) | Small molecule | L-type calcium channels (Cav1.2) | not yet graded | No reviewed efficacy summary in this indication | |
| OLOMAX | —(overall) | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuampin | —(overall) | Small molecule | HMG-CoA reductase / Calcium channel | not yet graded | No reviewed efficacy summary in this indication | |
| N0877 | Discontinued | Small molecule | Angiotensin II receptor / Thiazide diuretic | not yet graded | No reviewed efficacy summary in this indication | |
| SER-100 | Discontinued | Peptide | ORL-1 (nociceptin opioid-like receptor) | Weak signal | Featured results are safety only in this race |
Upcoming events
No upcoming readouts on record for this asset.